The emergence of Retatrutide ZPHC, at a concentration of 120mg, is sparking considerable excitement within the healthcare community. This novel dual GIP and GLP-1 agonist medication seems to deliver impressive improvements in fat shedding compared to existing therapies. Early clinical data have demonstrated substantial decreases in body fat percent